IntellaRx is a nonprofit opioid safety program run by Sevadar Foundation Inc., a 501(c)(3) public charity. It does two things for public agencies: it supplies the clinical context that prescription counts leave out, and it closes the identification gap in the medication and specimen chain. It does not prescribe, dispense, diagnose or treat.
If you have four minutes, this is the whole thing.
Why did cutting opioid prescriptions not reduce overdose deaths?
For twenty years, policy on the opioid crisis has been aimed at the number of prescriptions written. That number came down. Opioid-involved overdose deaths did not follow it down — they rose 95% between 2016 and their 2022 peak, before falling sharply in 2024 and 2025, driven throughout by an illicit supply that prescribing rules do not touch.
Meanwhile the analytics used to find bad actors read prescription counts and doses without knowing a patient’s diagnosis or a clinician’s intent. That instrument cannot tell a pill mill from the one specialist in a region who takes the hardest patients, so it flags both. Patients caught in the middle lose access, and the evidence on what happens to them is consistent: more overdose, more mental health crisis, more people leaving care altogether.
What does IntellaRx do?
- Supplies the missing clinical context — diagnosis, treatment plan, prior therapy, comorbidity, metabolic profile — to the people making decisions at the moment they make them.
- Closes the identification gap in the medication and specimen chain, so a controlled medication reaches the person it was written for and a test result belongs to the person it is attached to.
Around those sit delivery partnerships, behavioral health screening, social determinants assessment, safe storage and naloxone, and population-level analysis of what is actually in the local drug supply.
Is IntellaRx a pharmacy, a clinic or an enforcement agency?
It is not a pharmacy or a clinic — IntellaRx does not prescribe, dispense, diagnose or treat. It is not an enforcement instrument. It does not score patients by suspicion. It does not monitor individuals’ social media. And it does not tell any agency what its own regulatory obligations are, because that is a legal determination about that agency and it belongs to its counsel.
What does IntellaRx admit the evidence does not show?
Saying so is worth its own paragraph, because it is unusual. A federally funded systematic review found that no study has evaluated whether urine drug testing mitigates risk in opioid prescribing. There is no US estimate of the share of diversion caused by identity fraud. Randomized trials of pharmacogenomic-guided opioid therapy show no benefit on pain outcomes. All three of those are on this site at full prominence, on what is not established, along with figures from our own founding material that turned out to be wrong.
Who runs IntellaRx?
Sevadar Foundation Inc., a 501(c)(3) public charity, EIN 93-2840861. IntellaRx is a division and trade name of that foundation, not a separate company.
Frequently asked questions
What happens to patients who lose access to their opioids?
The evidence is consistent: more overdose, more mental health crisis, and more people leaving care altogether. Those patients are usually caught in the middle when prescription-count analytics cannot tell a pill mill from the one specialist in a region who takes the hardest cases, and flag both. The program’s first job, supplying the missing clinical context, is aimed at exactly that failure.
Does IntellaRx score patients or watch their social media?
No. IntellaRx is not an enforcement instrument. It does not score patients by suspicion and it does not monitor individuals’ social media. Its identification work exists so that a controlled medication reaches the person it was written for, and a test result belongs to the person it is attached to.
What else does the IntellaRx program include?
Around its two core jobs sit delivery partnerships, behavioral health screening, social determinants assessment, safe storage and naloxone, and population-level analysis of what is actually in the local drug supply. The full list, with what each one is and is not, is on the components page.
Longer versions: the argument in eight steps · the components · how engagement works.